PT  - JOURNAL ARTICLE
AU  - Haider, Najmul
AU  - Hasan, Mohammad Nayeem
AU  - Khan, Rumi A
AU  - McCoy, David
AU  - Ntoumi, Francine
AU  - Dar, Osman
AU  - Ansumana, Rashid
AU  - Uddin, Md. Jamal
AU  - Zumla, Alimuddin
AU  - Kock, Richard A
TI  - The Global case-fatality rate of COVID-19 has been declining disproportionately between top vaccinated countries and the rest of the world
AID  - 10.1101/2022.01.19.22269493
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.19.22269493
4099  - http://medrxiv.org/content/early/2022/01/21/2022.01.19.22269493.short
4100  - http://medrxiv.org/content/early/2022/01/21/2022.01.19.22269493.full
AB  - Globally 58.83% human population received at least one dose of the COVID-19 vaccines as of 5 January 2021. COVID-19 vaccination rollout is progressing at varied rates globally and data on the impact of mass vaccination on infection and case-fatality rates require definition. We compared the global reported cumulative case-fatality rate (rCFR) between top-20 countries with COVID-19 vaccination rates (>125 doses/100 people) and the rest of the world, before and after commencement of vaccination programmes.We considered the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-vaccine period (Jan 1, 2020 – Jan 5, 2021) and the post-vaccine period (Jan 6, 2021-Jan 5, 2022). We used a Generalized linear mixed model (GLMM) with a beta distribution to investigate the association between the CFR and potential predictors of each country and reported the relative risk (RR) of each variable.The mean rCFR of COVID-19 in the top-20 countries with vaccination rates was 1.83 (95% CI: 1.24-2.43) on 5 Jan 2021 and 1.18 (95% CI: 0.73-1.62) on 5 Jan 2022. The CFR for the rest of the world on 5 Jan 2021 was 2.32 (95% CI: 1.86-2.79) and 2.20 (95% CI: 1.86-2.55) on 5 January 2022. In Sub-Saharan Africa, the CFR remained roughly unchanged at 1.97 (95% CI: 1.59-2.35) on 5 Jan 2021 and 1.98 (95% CI:1.58-2.37) on 5 Jan 2022. The GLMM showed vaccination (/100 population) (RR:0.37) and Stringency Index (RR:0.88) were strong protective factors for the country’s COVID-19 CFR indicating that both vaccination and lockdown measures help in the reduction of COVID-19 CFR.The rCFR of COVID-19 continues to decline, although at a disproportionate rate between top vaccinated countries and the rest of the world. Vaccine equity and faster roll-out across the world is critically important in reducing COVID-19 transmission and CFR.What is already knownVaccination can reduce the case-fatality rate of COVID-19. Globally, the COVID-19 vaccination rollout is progressing at varied rates.What are the new findingsIn the top-20 countries with vaccination, >200 doses of vaccines are given per 100 people on 5th Jan 2022, In the rest of the word, the figure is 105, and in Sub-Saharan Africa (SSA) only 15.72After the introduction of COVID-19 vaccination the reported case-fatality rate (rCFR) of COVID-19 has reduced by 35% in the top-20 countries with vaccination, 8% in the rest of the world roughly unchanged in SSA.The doses of COVID-19 vaccines (/100 people) and rCFR has a negative correlation on 5 Jan 2022 (r=-0.296, p<0.001).The COVID-19 vaccination and Stringency Index are strong protective factors for the country’s COVID-19 rCFR indicating that both vaccination and lockdown measures help in reduction of COVID-19 rCFR.What do the new findings implyThe disproportionate case-fatality rate of COVID-19 between top vaccinated countries and the rest of the world demand fast and equitable vaccine rollout globally to reduce COVID-19 transmission and CFRCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding for this research.NH, FN, OD, RA AZ, RK are part of PANDORA-ID-NET Consortium (EDCTP Reg/Grant RIA2016E-1609) funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme, which is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data presented in this manuscript are publicly available in "Our World in Data", "WHO" or "United Nations" webpages. However, the corresponding author can be reached to specific queries on the data sources.